IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel...
Beyfortus® (nirsevimab) now available in Malaysia to protect all infants against RSV disease
Beyfortus® (nirsevimab) is an available option designed to protect all infants – whether born full-term or pre-term, healthy or with underlying conditions – against respiratory syncytial virus (RSV), with proven high and sustained efficacy, a...
Tuniu Receives Approval to Transfer to Nasdaq Capital Market and Extension of Minimum Bid Price Compliance Period
NANJING, China, Nov. 21, 2025 /PRNewswire/ -- Tuniu Corporation (NASDAQ:TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today announced that on November 20, 2025, the Listing Qualifications department of the...
EZGO Announces 1-for-25 Reverse Share Split Effective November 21, 2025
CHANGZHOU, China, Nov. 19, 2025 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we," "our," or the "Company"), a leading short-distance transportation solutions provider in China, today announced that on November 7, 2025, its board...
HKUST Receives Government's Approval to Establish a New Medical School
Dedicated to Nurturing a New Generation of Doctors Supporting Hong Kong Become a Hub for Medical Innovation HONG KONG, Nov. 18, 2025 /PRNewswire/ -- The establishment of Hong Kong's third medical school at The Hong Kong University of Science and...
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for...
LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction
BEIJING, Nov. 4, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new...
Rhythm of Numbers Across Millennia • Dialogue with the World ---- The Series of Commemoration Activities for the Anniversary of Liu Hui's Birth Held in Seoul, the Republic of Korea
BEIJING, Nov. 4, 2025 /PRNewswire/ -- On October 24, 2025, the "Rhythm of Numbers Across Millennia •Dialogue with the World" —— The Series of Commemoration Activities for the Anniversary of Liu Hui's Birth successfully commenced in Seoul, the...
Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO
Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics...
Visionary Holdings Inc. 2025 Annual General Meeting Concludes Successfully: Completes Board Renewal, Anchors New Direction for Compliant Development
TORONTO, Oct. 31, 2025 /PRNewswire/ -- Visionary Holdings Inc. (hereinafter referred to as the "Company"; a diversified enterprise registered in Ontario, Canada and listed on the Nasdaq Capital Market under the ticker symbol: GV) successfully held...